From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Sources Sought for Universal Influenza Vaccines

by Global Biodefense Staff
August 29, 2014
Pandemic Influenza Research

The Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) has issued a sources sought notice for the development of universal influenza vaccine candidates towards FDA licensure.

These improved vaccines will offer greater effectiveness over a wider array of strains within an influenza virus subtype and greater duration of protection over the currently licensed influenza vaccines. Improved vaccines will also have greater effectiveness in populations like the young, elderly, and immunocompromised which do not respond well to the currently licensed influenza vaccines.

The minimum mandatory eligibility criteria are as follows:

Demonstration of Advanced Development of the Proposed Universal Vaccine Candidate – Completion of Phase I clinical trials for safety and immunogenicity for an improved influenza virus vaccine by the time of contract proposal submission.

Plans for U.S. Vaccine Product Licensure – Demonstrate this commitment by documenting the submission of a US IND for the proposed universal influenza vaccine candidate.

U.S. Vaccine Manufacturing Capability – Written commitment to do the technology transfers and/or to establish a domestic capability necessary to domestically manufacture, test, and release final container product containing a universal influenza vaccine candidate within 12 weeks of a pandemic declaration with a manufacturing surge capacity of 50 million doses within six months.

Further details are available under Solicitation Number: SS-BARDA-2014-UNIVERSALINFLUENZA-0001. Responses are being accepted until September 1, 2014.

From Our Partners
Tags: ASPRBARDAHHSInfluenzaRFIVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC